Journal issues > Issue 5, November 2014 > Highlights in endocrine and neuroendocrine tumours

Highlights in endocrine and neuroendocrine tumours

The 2014 annual meeting of the European Society for Medical Oncology (ESMO) featured a number of interesting studies in endocrine and neuroendocrine oncology. This report will first focus on two presentations regarding lenvatinib in the treatment of thyroid cancers. In addition to this, the final OS of the RADIANT-3 study, evaluating everolimus in patients with advanced pancreatic neuroendocrine tumours (NET), will be summarized. The last part of the report will focus on the molecular profiling of NETs and discusses a study assessing the quality of life in NET patients using lanreotide autogel.

(BELG J MED ONCOL 2014;8(4):163–5)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €2.42

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top